Staying ahead of client demands in the annuity product game is no simple feat for even the most informed of financial advisors, and the latest trend may prove even more crucial to successful advising—it involves not a new product or rider, but an entire market for annuities.
Newly developed uniform transfer standards and increased availability have caused so-called “secondary market annuities” to surge in popularity amongst clients in their quest to find financial products with above-average interest rates to supplement retirement income. What once was a niche market is gaining traction with the ordinary investor, and it is time for all advisors to get up to speed.
A Primer on Secondary Market Annuities
Most secondary market annuities (also known as “factored” structured settlements) are annuities that were originally issued pursuant to structured settlements, meaning that the defendant in a lawsuit (often a personal injury suit) is found liable and, rather than pay damages to the plaintiff up front, reaches an agreement with the court so that the plaintiff receives the right to guaranteed annuity payments over time. In many cases, however, the plaintiff ends up needing the funds immediately and, through a court-approved process, transfers the right to guaranteed payments under the annuity to a third-party buyer for a lump sum.
Best Shipping Stocks To Watch Right Now: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.
Top Companies To Buy For 2014: Songbird Estates PLC (SBEPF.PK)
Songbird Estates plc is engaged in management of its investment in its main subsidiary, Canary Wharf Group plc (Canary Wharf Group), which is the holding company. Canary Wharf Group is engaged in integrated property development, investment and management focusing primarily on the Estate. In London, Canary Wharf Group is engaged through joint ventures in the redevelopment of 20 Fenchurch Street and the Shell Centre. Canary Wharf Group�� investment property portfolio consists of 16 completed properties (out of the approximately 35constructed on the Estate) totaling approximately seven meter square feet of net internal area (NIA). In July 2013, Songbird Estates plc's Canary Wharf Group plc completed the acquisition from Gort Limited (in administration) and Hibernia (2005) Limited (in administration), of 15 Westferry Circus at Canary Wharf. Advisors' Opinion:- [By Mike Arnold]
Brookfield's public assets include a 21% stake (and potentially more given certain warrants held by Brookfield) in General Growth Properties (GGP), a 51% stake in Brookfield Office Properties (BPO), a 36% stake (again, more if certain warrants are exercised) in Rouse Properties (RSE) and 21% stake in Canary Wharf Group Plc, which is majority owned by Songbird Estates Plc (SBEPF.PK).
Top Companies To Buy For 2014: Carnival Corporation(CCL)
Carnival Corporation operates as a cruise and vacation company. It provides cruises to various vacation destinations with a portfolio of cruise brands comprising Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn in North America; and AIDA Cruises, Costa Cruises, Cunard, Ibero Cruises, and P&O Cruises in Europe, Australia, and Asia. The company also involves in operation of hotels, as well as offers tour and transportation services. It operates approximately 98 ships, as well as owns and operates 15 hotels or lodges that include 3,420 guest rooms; 395 motorcoaches; and 20 domed rail cars. The company sells its cruises through travel agents, including wholesalers and tour operators. Carnival Corporation was founded in 1974 and is headquartered in Miami, Florida.
Advisors' Opinion:- [By Rick Munarriz]
After 34 years,�Carnival� (NYSE: CCL ) CEO Micky Arison is stepping down as CEO of the world's largest cruise-ship operator.
Carnival's new CEO is Arnold Donald. He's a longtime board member, so he naturally knows the company and its present challenges well. He lives in St. Louis, ironically enough, far removed from the coastal ports that Carnival relies on for most of its sailings.�
- [By Wallace Witkowski]
A handful of companies report earnings this week including Walgreen Co. (WAG) , Carnival Corp. (CCL) , Accenture PLC (ACN) , Red Hat Inc. (RHT) , Paychex Inc. (PAYX) , and GameStop Corp. (GME) First-quarter earnings season won�� be in full swing until mid-April when J.P. Morgan Chase & Co. (JPM) �reports.
- [By Rick Munarriz]
Waters remain choppy for Carnival (NYSE: CCL ) .
At a time when many consumer stocks are trading near their all-time highs, Carnival stock is trading closer to its 52-week low.
Top Companies To Buy For 2014: Vodafone Group PLC (VOD)
Vodafone Group Plc (Vodafone), incorporated in 1984, is a mobile communications company operating across the globe providing a range of communications services. The Company offers a range of products and services, including voice, messaging, data and fixed-line solutions and devices to assist customers in meeting their total communications needs. Vodafone has a global presence, with equity interests in over 30 countries and over 40 partner markets worldwide. It operates in three geographic regions: Europe, Africa and Central Europe; Asia Pacific, and the Middle East, and has an investment in Verizon Wireless in the United States. In October 2010, Vodafone Global Enterprise, the business within Vodafone, announced the acquisition of two telecom expense management (TEM) companies, Quickcomm and TnT Expense Management. In November 2011, the Company sold 24.4% interest in Polkomtel in Poland. In March 2012, Verizon Wireless, which is a joint venture of Verizon Communications Inc. and Vodafone, purchased the operating assets of Cellular One of Northeast Pennsylvania from the Company. In April 2012, its Netherlands-based division, Vodafone Libertel BV, acquired Telespectrum-DJ. On October 31, 2012, the Company acquired TelstraClear Limited. In May 2013, Vodafone Group Plc announced launch of its carrier services business unit.
In Europe, the Company�� mobile subsidiaries and joint venture operate under the brand name Vodafone. Its associate in France operates as SFR and Neuf Cegetel, and its fixed-line communication businesses operate as Vodafone, Arcor, Tele2 and TeleTu. Vodafone�� subsidiaries in Africa and Central Europe operate under the Vodafone brand, or in the case of Vodacom and its mobile subsidiaries, the Vodacom and Gateway brands. Its joint venture in Poland operates as Polkomtel and its associate in Kenya operates as Safaricom. The Company�� subsidiaries and joint venture in Fiji operate under the Vodafone brand, and its joint venture in Australia operates under the brands V! odafone and 3. The Company�� associate in the United States operates under the brand Verizon Wireless.
Vodafone has an international customer base with 370 million mobile customers across the world as of March 31, 2011. Vodafone also caters to all business segments ranging from small-office-home-office (SoHo) and small-medium enterprises (SMEs) to corporates and multinational corporations. Through its subsidiaries, Vodafone directly owns and manages approximately 2,200 stores around the world. The Company also has around 10,300 Vodafone-branded stores run through franchise and exclusive dealer arrangements.
The Company�� range of handsets covers all its customer segments and price points, and is available in a variety of designs. During the fiscal year ended March 31, 2011 (fiscal 2011), 14 new handsets were released under its own brand and it shipped 5.8 million. In addition to handsets, it supplies a range of connected smart devices. It supplies the iPhone in 19 markets. During fiscal 2011, the Company launched its USB stick based on 4G/LTE technology in Germany and Verizon Wireless launched in the United States.; Vodafone WebBox; a smartphone roaming data plan that allows the European customers to use their home data plan abroad for only 2 a day to access the Internet, emails and applications; the Android-powered Vodafone 845 and 945 devices; Vodafone TV services; Vodafone 252, which comes pre-loaded with Vodafone M-Pesa for mobile payment services and a prepaid balance indicator that helps customers to keep track of their phone credit to avoid overspending; Vodafone M-Pesa in South Africa, Qatar and Fiji; 3G services in India, and LTE services by acquiring LTE spectrum in Germany.
The Company is a carrier of mobile voice traffic in the world providing domestic, international and roaming voice services to more than 370 million customers. Its networks sent and received over 292 billion text, picture, music and video messages during fiscal 2011. The Company ! serves mo! re than 75 million customers with data services, which allow access to the Internet, email and applications on their phones, tablets, laptops and netbooks. The Company provides a range of data products, including Machine-to-machine (��2M�� connections, which allow devices to communicate with one another via built-in mobile SIM cards; Third party billing; Financial services; Near field communication (��FC��, and Mobile advertising. The Company, as of March 31, 2011, served 5.3 million M2M connections around the world. NFC allows communication between devices when they are touched together or brought within a few centimetres of each other. The Company has mobile advertising business in 18 countries with a range of capabilities. Over six million customers use its fixed broadband services in 13 markets to meet their total communications needs. In addition, through Gateway, it provides wholesale carrier services to more than 40 African countries. Other service revenue includes business managed services, such as secure remote network access, and revenue from mobile virtual network operators generated from selling access to its network at the wholesale level. The Company�� enterprise customers range from small-office-home-office (��oHo�� businesses and small to medium-sized enterprises (��MEs��, through to domestic and multinational companies. The Company has 34 million enterprise customers accounting for around 9% of all customers and around 23% of service revenue. The Company focuses on SoHos and SMEs to provide customers with integrated fixed and mobile communications solutions. Vodafone Global Enterprise manages the communication needs of over 560 of the multinational corporate customers. It provides a range of managed services, such as Central Ordering, Device Manager, Spend Manager Solutions, Invoice Manager, Vodafone Neverfail and Telecoms management. The Company offers a range of total communications applications, as well as services for enterprise and consumer customers. Vodafone Alw! ays Best ! Connected software enables customers to stay connected to the Internet on the available connection wherever they are by automatically managing the switching between connection types including mobile broadband, Wi-Fi and LAN. Vodafone PC Backup is an online back-up and restores service that enables users to remotely store data securely and automatically via their Internet connection.
Advisors' Opinion:- [By Selena Maranjian]
Vodafone (NASDAQ: VOD ) gained 8%. The company holds a 45% stake in the successful Verizon Wireless business, with Verizon�holding the other 55%. Vodafone shareholders are watching to see whether Verizon buys out the remaining 45%. The company may be less attractive without the Wireless stake, so there isn't uniform support for a buyout. In the meantime, Vodafone has been a solid dividend payer and has been buying back shares as well.
No comments:
Post a Comment